Bioengineered hybrid spheroids integrating mesenchymal stem cells and metformin-loaded microspheres for the treatment of sepsis-induced liver injury - PubMed
4 days ago
- #Sepsis
- #Metformin
- #Mesenchymal Stem Cells
- Sepsis causes multi-organ dysfunction and accounts for 20% of global deaths.
- Current treatments for sepsis are limited to antibiotics and organ-supportive therapy.
- No FDA-approved drugs, cells, or biologics are available for sepsis treatment.
- Bioengineered hybrid spheroids (HS) combine mesenchymal stem cells (MSCs) and metformin-loaded microspheres (Met-MS).
- HS shows enhanced antioxidants, anti-inflammatory, and immunomodulatory activities.
- HS improves cell viability and protects liver hepatocytes from ROS and inflammatory cytokines.
- HS transplantation via the hepatic portal vein reduces sepsis-associated organ dysfunction.
- HS modulates TLR4/NF-kB signaling pathways and enhances hepatic regeneration.
- MSCargo (HS) is a promising therapeutic alternative for sepsis and other inflammatory diseases.